Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cancer

Interventions: Drug: Niraparib

First Posted Date: 2018-11-30

Last Posted Date: 2024-07-16

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT03759600

Locations: 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵
Hirosaki University Hospital, Hirosaki, Aomori, Japan
🇯🇵
Iwate Medical University Hospital, Morioka, Iwate, Japan

and more 30 locations

Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: Niraparib

First Posted Date: 2018-11-30

Last Posted Date: 2024-06-07

Lead Sponsor: Takeda

Target Recruit Count: 19

Registration Number: NCT03759587

Locations: 🇯🇵
Hirosaki University Hospital, Hirosaki, Aomori, Japan
🇯🇵
Iwate Medical University Hospital, Morioka, Iwate, Japan
🇯🇵
Kurume University Hospital, Kurume, Fukuoka, Japan

and more 24 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-925 in Healthy Volunteers and Participants With Narcolepsy

Phase 1

Completed

Conditions: Healthy Participants
Narcolepsy

Interventions: Drug: TAK-925
Drug: Placebo

First Posted Date: 2018-11-21

Last Posted Date: 2020-12-08

Lead Sponsor: Takeda

Target Recruit Count: 57

Registration Number: NCT03748979

Locations: 🇯🇵
PS Clinic, Fukuoka, Japan
🇯🇵
Sumida Hospital, Sumida-ku, Tokyo, Japan
🇯🇵
Hakata Clinic, Fukuoka, Japan

Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults

Phase 2

Completed

Conditions: Dengue Fever

Interventions: Biological: TDV

First Posted Date: 2018-11-19

Last Posted Date: 2024-04-10

Lead Sponsor: Takeda

Target Recruit Count: 30

Registration Number: NCT03746015

Locations: 🇺🇸
Optimal Research, Peoria, Illinois, United States
🇺🇸
Oregon Health and Science University, Portland, Oregon, United States

Study of the Safety, Pharmacodynamics, Efficacy, and PK of TIMP-GLIA in Subjects With Celiac Disease

Phase 2

Completed

Conditions: Celiac Disease

Interventions: Drug: TIMP-GLIA
Drug: Placebo

First Posted Date: 2018-11-13

Last Posted Date: 2020-08-12

Lead Sponsor: Takeda

Target Recruit Count: 34

Registration Number: NCT03738475

Locations: 🇺🇸
Advanced Clinical Research, West Jordan, Utah, United States
🇺🇸
Prism Clinical Research, Saint Paul, Minnesota, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 4 locations

Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"

Completed

Conditions: Untreated CD30-Positive Hodgkin's Lymphoma

Interventions: Drug: Brentuximab vedotin (Genetical Recombination)

First Posted Date: 2018-11-02

Last Posted Date: 2024-08-21

Lead Sponsor: Takeda

Target Recruit Count: 113

Registration Number: NCT03729609

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Rasagiline

First Posted Date: 2018-11-01

Last Posted Date: 2024-03-08

Lead Sponsor: Takeda

Target Recruit Count: 1021

Registration Number: NCT03727139

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants

Completed

Conditions: Crohn Disease
Colitis, Ulcerative

First Posted Date: 2018-10-18

Last Posted Date: 2024-05-30

Lead Sponsor: Takeda

Target Recruit Count: 409

Registration Number: NCT03710486

Locations: 🇪🇸
Hospital Clinico Universitario de Valencia, Valencia, Comunidad Valenciana, Spain
🇵🇹
Centro Hospitalar Universitario Lisboa Norte - Hospital de Santa Maria, Lisboa, Portugal
🇵🇹
Hospital Beatriz Angelo, Loures, Lisboa, Portugal

and more 23 locations

Phase 3 Study of Cx601 in Participants With Complex Perianal Fistulising Crohn's Disease

Phase 3

Completed

Conditions: Complex Perianal Fistulas in Adult Participants With Crohn's Disease

Interventions: Biological: Darvadstrocel

First Posted Date: 2018-10-16

Last Posted Date: 2024-06-10

Lead Sponsor: Takeda

Target Recruit Count: 22

Registration Number: NCT03706456

Locations: 🇯🇵
Sapporo Higashi Tokushukai Hospital, Sapporo, Hokkaido, Japan
🇯🇵
Mie University Hospital, Tsu, Mie, Japan
🇯🇵
Tohoku Rosai Hospital, Sendai, Miyagi, Japan

and more 8 locations

A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)

Phase 2

Completed

Conditions: 15q Duplication Syndrome
CDKL5 Deficiency Disease

Interventions: Drug: Soticlestat

First Posted Date: 2018-10-03

Last Posted Date: 2022-05-26

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT03694275

Locations: 🇺🇸
Center for Rare Neurological Diseases, Norcross, Georgia, United States
🇺🇸
Research Institute Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Center for Rare Neurological Diseases (CRND)--Massachusetts General Hospital, Boston, Massachusetts, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy